A Pilot Randomized Trial of Physical Therapy with Atomoxetine or Methylphenidate for Gait and Balance Impairment in Parkinson’s Disease (The TAME-PD Study)

Authors:

Abstract
Background: Gait impairment in Parkinson's disease (PD) responds poorly to dopaminergic therapy. Whether catecholaminergic augmentation of physical therapy (PT) improves outcomes has not been tested in randomized trials.Objective: To assess feasibility and preliminary effects of adding atomoxetine or methylphenidate to structured PT in PD.Methods: TAME-PD was a single-center, randomized, rater-blinded pilot trial. Participants were randomized to PT alone, PT + atomoxetine 10 mg/day, or PT + methylphenidate 20 mg/day for 12 weeks. The primary outcome was change in Mini-Balance Evaluation Systems Test (Mini-BESTest) score at week 12.Results: Of 23 randomized participants, 18 had complete baseline and week-12 Mini-BESTest data. The primary outcome did not differ significantly between groups (Kruskal-Wallis p=0.099). Nonetheless, median improvement was 4.0 points with atomoxetine + PT, 2.0 with PT alone, and 1.5 with methylphenidate + PT. The effect-size point estimate for atomoxetine + PT versus PT alone was large (Cliff's δ=0.54, 95% CI −0.08 to 0.86); 80% of atomoxetine participants achieved the 4-point minimal clinically important difference versus 29% with PT alone and 17% with methylphenidate + PT. In the mixed-effects model, atomoxetine + PT improved more than methylphenidate + PT (+2.26 points; p=0.033; Holm-adjusted p=0.26); neither medication differed significantly from PT alone. Pooled medication-arm analysis showed no advantage over PT alone (p=0.68).Conclusions: Although this under-enrolled pilot trial was not conclusive, participants who received atomoxetine + PT showed greater median improvement in balance. These preliminary findings support further study of atomoxetine as a PT adjunct in PD with gait instability.